Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Silvia Novello, С. В. Орлов et al.|The Lancet Oncology|2014Cited by 948
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyTony Mok, Lin Wu, Yi‐Long Wu et al.|Clinical Cancer Research|2015Cited by 469
Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expressionZhiwei Chen, Meilin Liao|Oncotarget|2017Cited by 4